Evidence map›Paper›PMID 26615615›Full record

Trial reportQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2016

Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology.

Momar Diouf, Thomas Filleron, Anne-Laure Pointet, Anne-Claire Dupont-Gossard, David Malka, Pascal Artru, Mélanie Gauthier, Thierry Lecomte, Thomas Aparicio, Anne Thirot-Bidault and 7 more

Abstract readClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Unraveling Racial Disparities in Supportive Care Medication Use among End-of-Life Pancreatic Cancer Patients: Focus on Pain Management and Psychiatric Therapies.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023
    Observational
  5. Multiview Deep Forest for Overall Survival Prediction in Cancer.Computational and mathematical methods in medicine · 2023
    Article
  6. Article
  7. Article
  8. Patterns of racial/ethnic disparities in baseline health-related quality of life and relationship with overall survival in patients with colorectal cancer.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2020
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 10 institutions in 1 country.

Momar DioufClinical Research and Innovation Directorate, Amiens University Hospital, Amiens, France. diouf.momar@chu-amiens.fr.
Thomas FilleronBiostatistics Unit, Claudius Régaud Institute, Toulouse, France.
Anne-Laure PointetHepatogastroenterology and Digestive Oncology Department, Hôpital Européen Georges Pompidou, Université Paris Descartes, Paris, France.
Anne-Claire Dupont-GossardCHU Jean Minjoz, Besançon, France.
David MalkaGustave Roussy, Villejuif, France.
Pascal ArtruHôpital Privé Jean Mermoz, Lyon, France.
Mélanie GauthierCentre Georges-François Leclerc, Dijon, France.
Thierry LecomteCHU de Tours-Hôpital Trousseau, Chambray-Les-Tours, France.
Thomas AparicioCHU Avicenne, Université Paris 13, Sorbonne Paris Cité, Bobigny, France.
Anne Thirot-BidaultCHU Bicêtre, Le Kremlin-Bicêtre, France.
Céline LobryCHU Bichat-Claude Bernard, Paris, France.
Francine FeinCHU Jean Minjoz, Besançon, France.
Olivier DubreuilHepatogastroenterology and Digestive Oncology Department, Hôpital Européen Georges Pompidou, Université Paris Descartes, Paris, France.
Bruno LandiHepatogastroenterology and Digestive Oncology Department, Hôpital Européen Georges Pompidou, Université Paris Descartes, Paris, France.
Aziz ZaananHepatogastroenterology and Digestive Oncology Department, Hôpital Européen Georges Pompidou, Université Paris Descartes, Paris, France.
Julien TaiebHepatogastroenterology and Digestive Oncology Department, Hôpital Européen Georges Pompidou, Université Paris Descartes, Paris, France. julien.taieb@egp.aphp.fr.
Franck BonnetainMethodology and Quality of Life in Oncology Unit, EA 3181 CHU Besançon and the Qualité de Vie et Cancer Clinical Research Platform, Besançon, France.
Université Paris Cité · FRCentre Hospitalier Universitaire de Besançon · FRMethodology and Quality of Life Unit in Oncology · FRBicêtre Hospital · FRCentre Georges François Leclerc · FRCentre Hospitalier Universitaire de Tours · FRHôpital Privé Jean Mermo · FRInstitut Claudius Regaud · FRInstitut Gustave Roussy · FRUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeEastern Cooperative Oncology Group Performance Status (ECOG-PS) is currently an important parameter in the choice of treatment strategy for metastatic pancreatic adenocarcinoma (mPA) patients. However, previous research has shown that patients' self-reported health-related quality of life (HRQOL) scales provided additional prognostic information in homogeneous groups of patients with respect to ECOG-PS. The aim of this study was to identify HRQOL scales with independent prognostic value in mPA and to propose prognostic groups for these patients.

methodsWe analysed data from 98 chemotherapy-naive patients with histologically proven mPA recruited from 2007 to 2011 in the FIRGEM phase II study which aimed to compare the effectiveness of two chemotherapy regimen. HRQOL data were assessed with the European Organization for Research and Treatment of Cancer QLQ-C30 questionnaire. A random survival forest methodology was used to impute missing data and to identify major prognostic factors for overall survival.

resultsBaseline HRQOL assessment was completed by 60 % of patients (59/98). Twelve prognostic variables were identified. The three most important prognostic variables were fatigue, appetite loss, and role functioning, followed by three laboratory variables. The model's discriminative power assessed by Harrell's C statistic was 0.65. Fatigue score explained almost all the survival variability.

conclusionHRQOL scores have prognostic value for mPA patients with good ECOG-PS. Moreover, the patient's fatigue, appetite loss, and self-perception of daily activities were more reliable prognostic indicators than clinical and laboratory variables. These HRQOL scores, especially the fatigue symptom, should be urgently included for prognostic assessment of mPA patients (with good ECOG-PS).

Indexed as

Self ConceptAdenocarcinomaAdultAgedAppetiteFatigueFemaleHumansMaleMiddle AgedPancreatic NeoplasmsPrognosisQuality of LifeSelf ReportSurveys and QuestionnairesMetastaticPancreatic adenocarcinomaPrognosisQuality of life

Identifiers

PMID26615615
OpenAlexW2179223759

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.